PALI
Price
$0.64
Change
-$0.03 (-4.48%)
Updated
Apr 3 closing price
Capitalization
2.96M
RNAC
Price
$12.34
Change
-$0.61 (-4.71%)
Updated
Apr 3 closing price
Capitalization
319.69M
Ad is loading...

PALI vs RNAC

Header iconPALI vs RNAC Comparison
Open Charts PALI vs RNACBanner chart's image
Palisade Bio
Price$0.64
Change-$0.03 (-4.48%)
Volume$25.88K
Capitalization2.96M
Cartesian Therapeutics
Price$12.34
Change-$0.61 (-4.71%)
Volume$83.67K
Capitalization319.69M
PALI vs RNAC Comparison Chart
Loading...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PALI vs. RNAC commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PALI is a Buy and RNAC is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (PALI: $0.64 vs. RNAC: $12.34)
Brand notoriety: PALI and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PALI: 7% vs. RNAC: 103%
Market capitalization -- PALI: $2.96M vs. RNAC: $319.69M
PALI [@Biotechnology] is valued at $2.96M. RNAC’s [@Biotechnology] market capitalization is $319.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PALI’s FA Score shows that 1 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • PALI’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, both PALI and RNAC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PALI’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • PALI’s TA Score: 4 bullish, 4 bearish.
  • RNAC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both PALI and RNAC are a good buy in the short-term.

Price Growth

PALI (@Biotechnology) experienced а -6.60% price change this week, while RNAC (@Biotechnology) price change was -14.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

PALI is expected to report earnings on May 11, 2023.

RNAC is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC($320M) has a higher market cap than PALI($2.96M). RNAC YTD gains are higher at: -31.100 vs. PALI (-60.970). PALI has higher annual earnings (EBITDA): -14.05M vs. RNAC (-75.99M). RNAC has more cash in the bank: 213M vs. PALI (8.04M). PALI has less debt than RNAC: PALI (357K) vs RNAC (14M). RNAC has higher revenues than PALI: RNAC (38.9M) vs PALI (0).
PALIRNACPALI / RNAC
Capitalization2.96M320M1%
EBITDA-14.05M-75.99M18%
Gain YTD-60.970-31.100196%
P/E Ratio0.02N/A-
Revenue038.9M-
Total Cash8.04M213M4%
Total Debt357K14M3%
FUNDAMENTALS RATINGS
PALI vs RNAC: Fundamental Ratings
PALI
RNAC
OUTLOOK RATING
1..100
9163
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9689
P/E GROWTH RATING
1..100
10034
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PALI's Valuation (18) in the null industry is significantly better than the same rating for RNAC (99) in the Biotechnology industry. This means that PALI’s stock grew significantly faster than RNAC’s over the last 12 months.

PALI's Profit vs Risk Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to RNAC’s over the last 12 months.

PALI's SMR Rating (99) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's Price Growth Rating (89) in the Biotechnology industry is in the same range as PALI (96) in the null industry. This means that RNAC’s stock grew similarly to PALI’s over the last 12 months.

RNAC's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for PALI (100) in the null industry. This means that RNAC’s stock grew significantly faster than PALI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PALIRNAC
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 24 days ago
86%
Bullish Trend 15 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GWAV0.23-0.01
-4.64%
Greenwave Technology Solutions Inc.
GTX7.60-0.59
-7.20%
Garrett Motion
LWLG0.90-0.10
-9.99%
Lightwave Logic
BIRD5.97-0.83
-12.21%
Allbirds Inc
APA17.74-3.50
-16.48%
APA Corp

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
-3.54%
RNAC - PALI
81%
Closely correlated
-4.71%
AGEN - PALI
81%
Closely correlated
-1.84%
NCNA - PALI
81%
Closely correlated
-5.57%
SNPX - PALI
81%
Closely correlated
-4.22%
ALLR - PALI
76%
Closely correlated
-7.03%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with SNPX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-4.71%
SNPX - RNAC
91%
Closely correlated
-4.22%
ALLR - RNAC
86%
Closely correlated
-7.03%
NRXP - RNAC
86%
Closely correlated
-6.97%
PALI - RNAC
81%
Closely correlated
-3.54%
HRTX - RNAC
37%
Loosely correlated
-4.04%
More